2015
DOI: 10.1016/j.brachy.2015.08.002
|View full text |Cite
|
Sign up to set email alerts
|

Skin dose in breast brachytherapy: Defining a robust metric

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 23 publications
(12 citation statements)
references
References 34 publications
0
12
0
Order By: Relevance
“…Clinical outcomes published at a median follow-up of 63 months found a local recurrence rate of 1.2 ± 1.2%, comparable to nomogram-based estimates for whole breast irradiation [8]. As the PBSI technique matures, numerous studies in recent literature have investigated how to optimize aspects of the treatment process, including treatment planning [9,10,11,12], training [13,14], clinical practice [15,16], and post-implant analysis [17,18,19,20,21].…”
Section: Purposementioning
confidence: 86%
“…Clinical outcomes published at a median follow-up of 63 months found a local recurrence rate of 1.2 ± 1.2%, comparable to nomogram-based estimates for whole breast irradiation [8]. As the PBSI technique matures, numerous studies in recent literature have investigated how to optimize aspects of the treatment process, including treatment planning [9,10,11,12], training [13,14], clinical practice [15,16], and post-implant analysis [17,18,19,20,21].…”
Section: Purposementioning
confidence: 86%
“…D 0.1cm3 , D 2cm3 ) are generally reported. Regarding the skin, in addition to the maximum surface point dose, reporting D 0.2cm3 or D 1cm3 [52] is recommended. Table 1 lists the most common dose-volume parameters used in interstitial breast brachytherapy.…”
Section: Dose-volume Parameters and Dose Constraintsmentioning
confidence: 99%
“…In the GEC-ESTRO study there was only one requirement for dose uniformity, namely the DNR < 0.35. According to the experience of the centres participating in the GEC-ESTRO study and respecting current available data [19,52,56,57] the recommended dose-volume constraints for the implant, PTV and organs at risk are presented in Tables 2 and 3. Since the dose to contralateral breast and lung is low in interstitial brachytherapy, no threshold is given for these organs, only a few parameters are recommended for reporting.…”
Section: Dose-volume Limits For Ptv and Oarsmentioning
confidence: 99%
“…Hilts et al . [42] recommend using D 0.2cm 3 for a 2-mm thick skin layer as a surrogate for dose to skin area of 1 cm 2 . In a paper of Lettmaier et al .…”
Section: Discussionmentioning
confidence: 99%